Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss			$ (44,989)	$ (42,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	$ 300	$ 400	647	674
Stock-based compensation			6,530	3,897
Research and development license expense				3,500
Change in fair value of warrant liability			142
Non-cash change in fair value of term loan			(268)
Non-cash lease expense			619	603
Other			1	387
Changes in operating assets and liabilities:
Prepaid expenses and other assets			129	509
Accounts payable			2,365	2,123
Accrued expenses and other liabilities			(1,955)	(1,324)
Deferred revenue			(4,523)	(7,101)
Net cash used in operating activities			(41,302)	(38,952)
Cash flows from investing activities
Purchase of property, plant and equipment			(341)	(3,852)
Net cash used in investing activities			(341)	(3,852)
Cash flows from financing activities
Debt issuance costs for term loan			(18)
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs			70,481
Payment of offering costs				(387)
Proceeds from common stock issuances under ESPP			26	50
Other			(43)	(156)
Net cash provided by financing activities			70,446	7
Net increase (decrease) in cash, cash equivalents and restricted cash			28,803	(42,797)
Cash, cash equivalents and restricted cash at the beginning of the period			146,540	90,517	$ 90,517
Cash, cash equivalents and restricted cash at the end of the period	175,343	47,720	175,343	47,720	146,540
Cash and cash equivalents	172,743	45,083	172,743	45,083	$ 143,940
Restricted cash	$ 2,600	$ 2,637	2,600	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest			2,655	2,399
Supplemental disclosure of noncash investing and financing activities:
Issuance of warrants in connection with private placement				252
Research and development license not yet paid				3,500
Offering costs not yet paid			$ 445
Private Placement
Cash flows from financing activities
Proceeds from issuance of common stock from private placement				$ 500